Salazar, Nurhaniza T.
HRN: 26-63-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/20/2025
CEFTRIAXONE 1G (VIAL)
02/20/2025
02/27/2025
IV
2g
Q 24H
S/P ORIF Clavicle
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes